shire map
Select a

Shire Global


Half Yearly Report

July 30, 2015 – Shire plc (the “Group”) (LSE: SHP, NASDAQ: SHPG), in accordance with the Financial Conduct Authority's Disclosure Rules and Transparency Rules, is publishing today its Half Yearly Report for the six months ended June 30, 2015.

It should be noted that on July 23, 2015 the Group previously announced its results in respect of the same period.

For further information please contact:

Investor Relations



Sarah Elton-Farr

+44 1256 894157




Michele Galen

+1 781 482 1867

Brooke Clarke

+44 1256 894 829

Download the PDF for the full release


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.


Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE